ArticleDiabetes care2021
Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database.
Article in Diabetes care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Guidelines for clinical evaluation of chronic kidney disease in early stages : AMED research on regulatory science of pharmaceuticals and medical devices.Clinical and experimental nephrology · 2024Guideline
- Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY.Clinical and experimental nephrology · 2024Trial
- Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus.Clinical and experimental nephrology · 2023Trial
- Efficacy and safety of SGLT2 inhibitors in elderly patients with type 2 diabetes.Annals of medicine · 2026Article
- SGLT2 inhibitors: mechanisms, physiology and pharmacology, and clinical applications.Molecular biomedicine · 2026Review
- The eGFR difference between creatinine-based and cystatin-C-based equations is also important in an Asian population within the J-CKD-DB-Ex.Scientific reports · 2026Observational
- Renin-angiotensin system inhibitor use and cardio-renal outcomes in non-proteinuric chronic kidney disease: a post-hoc analysis of the Frontier of Renal Outcome Modification-Japan study.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Evidence on SGLT2 Inhibitors' Efficacy in Older and Frail Patients.Journal of clinical medicine · 2026Review
- Association between early proteinuria reduction and kidney outcomes in Japanese patients with IgA nephropathy: The Japan Chronic Kidney Disease Database.Clinical and experimental nephrology · 2026Article
- Prediction of estimated glomerular filtration rate slope and kidney prognosis of patients with chronic kidney disease.Scientific reports · 2026Article
- Proteinuria reduction as a surrogate endpoint for clinical study of IgA nephropathy in Japanese patients: data from the J-CKD-DB-Ex.Clinical and experimental nephrology · 2026Observational
- Review no. 1: designing clinical kidney research using real-world data: research questions, data sources, and analytical skills.Clinical and experimental nephrology · 2026Review
- Empagliflozin slows down natural kidney senescence via Six1/Wnt4/NF-κB pathway.Biogerontology · 2025Article
- Transitional changes in medication-initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes-A hospital-based cohort study in Japan.Diabetes, obesity & metabolism · 2025Article
- The Future of Chronic Kidney Disease Treatment: Combination Therapy (Polypill) or Biomarker-Guided Personalized Intervention?Biomolecules · 2025Review
- Public Data in Nephrology: A Researcher's Roadmap.Kidney international reports · 2025Article
- Development and validation of an algorithm for identifying patients undergoing dialysis from patients with advanced chronic kidney disease.Clinical and experimental nephrology · 2025Article
- Changes in body composition and handgrip strength during dapagliflozin administration in patients with chronic kidney disease.Clinical kidney journal · 2025Article
- Sodium-Glucose Cotransporter-2 Inhibitors and Prevention of Adverse Kidney Outcomes in Type 2 Diabetes: A Clinical Multiethnic Asian Cohort.Kidney medicine · 2025Article
- Kidney outcomes with SGLT2 inhibitor versus DPP4 inhibitor use in older adults with diabetes.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 20 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveRandomized controlled trials have shown kidney-protective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested that these effects translate to clinical practice. However, long-term efficacy, as well as whether the presence or absence of proteinuria and the rate of estimated glomerular filtration rates (eGFR) decline prior to SGLT2 inhibitor initiation modify treatment efficacy among type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) patients, is unknown. RESEARCH DESIGN AND
methodsUsing the Japan Chronic Kidney Disease Database (J-CKD-DB), a nationwide multicenter CKD registry, we developed propensity scores for SGLT2 inhibitor initiation, with 1:1 matching with patients who were initiated on other glucose-lowering drugs. The primary outcome included rate of eGFR decline, and the secondary outcomes included a composite outcome of 50% eGFR decline or end-stage kidney disease.
resultsAt baseline, mean age at initiation of the SGLT2 inhibitor (
conclusionsThe benefits of SGLT2 inhibitors on kidney function as observed in clinical trials translate to patients treated in clinical practice with no evidence that the effects are modified by the underlying rate of kidney function decline or the presence of proteinuria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.